Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

NCT03189836 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT03189836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03189836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Lead sponsor
Cogent Biosciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 4, 2017
Completion date
September 21, 2020
Enrollment
26 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma